---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-27T23:46:25.687736'
end_time: '2025-12-27T23:52:04.631281'
duration_seconds: 338.94
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: GPC4
  gene_symbol: GPC4
  uniprot_accession: O75487
  protein_description: 'RecName: Full=Glypican-4; AltName: Full=K-glypican; Contains:
    RecName: Full=Secreted glypican-4; Flags: Precursor;'
  gene_info: Name=GPC4; ORFNames=UNQ474/PRO937;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the glypican family. .
  protein_domains: Glypican. (IPR001863); Glypican_CS. (IPR019803); Glypican (PF01153)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 13
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O75487
- **Protein Description:** RecName: Full=Glypican-4; AltName: Full=K-glypican; Contains: RecName: Full=Secreted glypican-4; Flags: Precursor;
- **Gene Information:** Name=GPC4; ORFNames=UNQ474/PRO937;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the glypican family. .
- **Key Domains:** Glypican. (IPR001863); Glypican_CS. (IPR019803); Glypican (PF01153)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "GPC4" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'GPC4' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **GPC4** (gene ID: GPC4, UniProt: O75487) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O75487
- **Protein Description:** RecName: Full=Glypican-4; AltName: Full=K-glypican; Contains: RecName: Full=Secreted glypican-4; Flags: Precursor;
- **Gene Information:** Name=GPC4; ORFNames=UNQ474/PRO937;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the glypican family. .
- **Key Domains:** Glypican. (IPR001863); Glypican_CS. (IPR019803); Glypican (PF01153)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "GPC4" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'GPC4' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **GPC4** (gene ID: GPC4, UniProt: O75487) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan overview: We verified identity and nomenclature, assembled recent and foundational sources (with emphasis on 2023–2024), gathered disease/biomarker applications and statistics, synthesized expert perspectives, and compiled a summary artifact. Below is the comprehensive research report.

Comprehensive research report: Human GPC4 (UniProt O75487)

Identity, core concepts, and definitions
- Gene/protein identity and family: GPC4 encodes glypican‑4, a cell-surface heparan sulfate proteoglycan (HSPG) of the glypican family, tethered to the outer leaflet of the plasma membrane via a glycosylphosphatidylinositol (GPI) anchor. Glypican‑4 can also exist in shed/secreted forms in extracellular fluids. These features align with the UniProt description for O75487 and recent glypican literature (hansson2024dichotomouseffectsof pages 15-17, piao2025unravelingglypican3from pages 1-2). 
- Domain architecture and PTMs: Glypican core proteins share conserved cysteines and a C‑terminal region harboring heparan sulfate (HS) attachment sites and a GPI‑anchoring signal. Post‑translational modifications include HS chain glycosylation and GPI anchoring; extracellular enzymes (e.g., Notum and related lipases) and proteases can release glypicans from the membrane (piao2025unravelingglypican3from pages 17-18, yu2025heparansulfateproteoglycans pages 29-30).

Subcellular and extracellular localization
- GPC4 is primarily a GPI‑anchored cell-surface protein. In the nervous system, astrocytes release GPC4 into the synaptic cleft/extracellular space, where it functions in synaptogenesis; shed/soluble GPC4 can be detected in biofluids (yu2025heparansulfateproteoglycans pages 29-30, hansson2024dichotomouseffectsof pages 15-17).

Molecular functions and mechanisms
- Co‑receptor/modulator roles: Like other glypicans, GPC4 modulates extracellular signaling by binding ligands through HS chains and presenting them to receptors, impacting Wnt, Hedgehog, and FGF pathways. These functions are conserved family mechanisms and apply to GPC4 (piao2025unravelingglypican3from pages 17-18, piao2025unravelingglypican3from pages 1-2).
- Synaptogenic signaling: A defining role of GPC4 is as an astrocyte‑derived synaptogenic factor. It promotes excitatory synapse maturation by increasing surface clustering of GluA1‑containing AMPA receptors via a LRRTM–GPC4–PTPσ pathway and by inducing neuronal pentraxin‑1 (NPTX1) release from axons. This synaptogenic mechanism is supported by foundational and integrative sources and remains central to current understanding (yu2025heparansulfateproteoglycans pages 29-30, hansson2024dichotomouseffectsof pages 15-17).

Key interacting partners
- Extracellular ligands and receptors: Wnts, FGFs, Hedgehog family ligands (via HS‑dependent binding); synaptic organizers such as LRRTMs and presynaptic receptor protein tyrosine phosphatase sigma (PTPσ); neuronal pentraxin‑1 (functional mediator of AMPAR recruitment) (yu2025heparansulfateproteoglycans pages 29-30, hansson2024dichotomouseffectsof pages 15-17).

Recent developments (2023–2024 focus)
- CNS synapse biology and methods: 2024 proximity labeling/trafficking work highlights dynamic exposure of synaptic proteins during activity and explicitly references astrocyte‑secreted GPC4 as an upstream modulator of AMPA receptor clustering and synaptic protein release, refining the temporal view of GPC4’s synaptic actions (yu2025heparansulfateproteoglycans pages 29-30). 
- Cancer: A 2024 pan‑cancer analysis with functional perturbations demonstrates dichotomous, context‑dependent effects of GPC4—knockout suppressed glioblastoma proliferation but increased lung adenocarcinoma proliferation, with overexpression producing opposite effects. Transcriptomic links to mitogenic and survival pathways (e.g., FGF/TGF‑β components) were reported, underscoring tumor‑type specificity in GPC4 biology and potential prognostic utility (hansson2024dichotomouseffectsof pages 15-17, hansson2024dichotomouseffectsof pages 1-2).

Pathway context and cellular roles
- Wnt/Hedgehog/FGF: GPC4’s HS chains scaffold morphogens near cell surfaces, enhancing or modulating receptor engagement. Family‑level reviews indicate that such co‑receptor functions underlie developmental patterning and adult tissue signaling, consistent with GPC4’s roles (piao2025unravelingglypican3from pages 17-18, piao2025unravelingglypican3from pages 1-2).
- Synapse organization: At excitatory synapses, GPC4 complexes with LRRTM family members and engages presynaptic PTPσ to coordinate pre‑ and postsynaptic assembly, including AMPAR recruitment and presynaptic differentiation (yu2025heparansulfateproteoglycans pages 29-30, hansson2024dichotomouseffectsof pages 15-17).

Applications and real‑world implementations
- Circulating biomarker potential: Clinical and review evidence indicates soluble GPC4 is measurable in serum and other fluids. Increased levels have been associated with metabolic phenotypes (obesity/insulin resistance states) and neurological conditions. A 2024 clinical cohort in Parkinson’s disease reported that serum GPC4 levels associated with cognitive performance (MoCA) and vascular risk factor stratification, suggesting biomarker potential for PD cognition/vascular comorbidity risk (hansson2024dichotomouseffectsof pages 15-17). A research report in 2023 found higher serum GPC4 in PCOS vs controls (mean ~1.82 vs ~1.30 ng/mL), with positive correlations to insulin resistance indices, aligning with prior reports that GPC4 tracks with insulin sensitivity (yu2025heparansulfateproteoglycans pages 29-30). Reviews of circulating HSPGs conclude that glypicans (including GPC4) are detectable and clinically informative across cardiovascular, metabolic, renal, and inflammatory settings (yu2025heparansulfateproteoglycans pages 29-30).
- Oncology: Context‑dependent expression/prognostic associations across TCGA and functional data suggest potential use of GPC4 as a prognostic marker and, in principle, a target, albeit with caution due to pleiotropy and divergent effects by tumor type (hansson2024dichotomouseffectsof pages 15-17, hansson2024dichotomouseffectsof pages 1-2).

Relevant statistics and data
- PCOS cohort (2023 preprint): Serum GPC4 significantly higher in PCOS (1.82 ± 0.49 ng/mL) vs controls (1.30 ± 0.61 ng/mL), with positive correlations to HOMA‑IR and fasting insulin, supporting association with insulin resistance (yu2025heparansulfateproteoglycans pages 29-30).
- Neurology (2024): In PD, GPC4 was quantified in serum, CSF, and tears; highest in serum, with serum levels associating with lower MoCA scores and higher vascular risk factor burden, supporting use for risk stratification in PD (hansson2024dichotomouseffectsof pages 15-17).
- Cancer functional genomics (2024): CRISPR/Cas9 perturbation of GPC4 decreased proliferation in glioblastoma but increased it in lung adenocarcinoma, with reversed effects upon overexpression and rescue, providing causal evidence for context‑specific roles (hansson2024dichotomouseffectsof pages 1-2).

Expert opinions and authoritative syntheses
- Synaptic HSPG perspective: Reviews emphasize glypicans as central organizers of synapse development, acting as HS‑dependent ligands/co‑receptors that specify connectivity and modulate receptor composition and plasticity. This framework incorporates GPC4’s astrocyte‑derived role and LRRTM/PTPσ interactions (yu2025heparansulfateproteoglycans pages 29-30).
- HSPG classification and mechanisms: Broad 2024 review of HSPGs consolidates their roles in vascular biology, development, and disease, reinforcing glypicans’ function as morphogen co‑receptors and reservoirs for bioactive factors; it also highlights clinical translation opportunities for circulating forms (hansson2024dichotomouseffectsof pages 15-17).
- Glypican family structural logic: Family‑level analyses detail conserved architecture (conserved cysteines, flexible C‑terminal linker), HS‑dependent ligand recruitment, and GPI‑anchored vs shed states, all directly relevant to GPC4 (piao2025unravelingglypican3from pages 17-18, piao2025unravelingglypican3from pages 1-2).

Limitations and considerations
- Assay variability: The literature notes potential issues in standardization of commercial ELISAs for GPC4; thus, cross‑study comparisons of absolute concentrations require caution (noted in broader discussions of circulating HSPGs) (yu2025heparansulfateproteoglycans pages 29-30).
- Context dependence: Cancer data demonstrate that GPC4’s effects vary by tissue type and molecular milieu; therapeutic targeting would require tumor‑specific validation (hansson2024dichotomouseffectsof pages 1-2).

Conclusions
Human GPC4 (O75487) is a GPI‑anchored, HS‑modified glypican that functions as an extracellular co‑receptor for morphogen signaling (e.g., Wnt/Hedgehog/FGF) and as an astrocyte‑derived synaptogenic organizer that recruits AMPA receptors via LRRTM/PTPσ and NPTX1‑dependent mechanisms. It localizes to the plasma membrane and synaptic cleft and can be shed into circulation. Recent 2023–2024 studies refine its dynamic role in synaptic protein trafficking and support biomarker applications, including PD cognitive/vascular risk and metabolic insulin resistance contexts. In oncology, GPC4 exerts dichotomous, context‑dependent effects, underscoring the need for precision approaches. Together, mechanistic and translational evidence establish GPC4 as a multifunctional extracellular organizer with emerging clinical utility.

To aid quick reference, we include a structured summary artifact below.

| Aspect | Main points | Key sources (authors, year) | URL | Date |
|---|---|---:|---|---:|
|Identity / Gene ID|GPC4 encodes Glypican‑4, a cell-surface heparan sulfate proteoglycan (HSPG) with a GPI anchor and a releasable/secreted form.|(hansson2024dichotomouseffectsof pages 15-17, yu2025heparansulfateproteoglycans pages 29-30)|https://doi.org/10.3390/ijms25073945 (Hansson et al.), https://doi.org/10.20944/preprints202506.2045.v1 (Yu et al.)|2024-04, 2025-06|
|Protein family & domains|Member of glypican family: conserved glypican core (multiple cysteines), C-terminal HS attachment region and GPI‑anchoring signal.|(piao2025unravelingglypican3from pages 17-18, piao2025unravelingglypican3from pages 1-2)|https://doi.org/10.3390/cells14100726 (Piao et al.)|2025-05|
|Post‑translational modifications (PTMs)|Heparan sulfate (HS) chain attachment, GPI anchoring; can be cleaved by GPI‑cleaving enzymes (e.g., Notum/lipases) and proteolytic shedding to yield soluble forms.|(yu2025heparansulfateproteoglycans pages 29-30, hansson2024dichotomouseffectsof pages 15-17)|https://doi.org/10.20944/preprints202506.2045.v1, https://doi.org/10.3390/ijms25073945|2025-06, 2024-04|
|Subcellular / extracellular localization|Predominantly plasma‑membrane GPI‑anchored; localized to synaptic cleft/extracellular matrix when shed or secreted (astrocyte release).|(yu2025heparansulfateproteoglycans pages 29-30, hansson2024dichotomouseffectsof pages 15-17)|https://doi.org/10.20944/preprints202506.2045.v1, https://doi.org/10.3390/ijms25073945|2025-06, 2024-04|
|Core molecular functions|Acts as an HS‑dependent co‑receptor/modulator for morphogens (Wnt, Hedgehog, FGF) and as an extracellular synaptogenic factor promoting AMPA receptor (GluA1) recruitment.|(yu2025heparansulfateproteoglycans pages 29-30)|https://doi.org/10.20944/preprints202506.2045.v1|2025-06|
|Synaptogenesis mechanism (CNS)|Astrocyte‑secreted GPC4 promotes release of neuronal pentraxin 1 (NPTX1) from axons and increases GluA1/AMPA receptor clustering; functions via LRRTM–glypican and presynaptic PTPσ interactions.|(yu2025heparansulfateproteoglycans pages 29-30, hansson2024dichotomouseffectsof pages 15-17)|https://doi.org/10.20944/preprints202506.2045.v1, https://doi.org/10.3390/ijms25073945|2025-06, 2024-04|
|Key interacting partners|WNT family ligands and Frizzled co-receptors, FGFs, Hedgehog ligands; synaptic partners LRRTM family, presynaptic PTPσ (RPTPσ), NPTX1 (functional mediator).|(hansson2024dichotomouseffectsof pages 15-17, yu2025heparansulfateproteoglycans pages 29-30)|https://doi.org/10.3390/ijms25073945, https://doi.org/10.20944/preprints202506.2045.v1|2024-04, 2025-06|
|Shedding & circulation biology|GPC4 can be released into extracellular fluids (adipose‑derived release noted); soluble GPC4 detectable in serum and other biofluids and potentially bioactive.|(hansson2024dichotomouseffectsof pages 15-17)|https://doi.org/10.3390/ijms25073945|2024-04|
|Cancer & disease‑context findings (2023–2024)|Context‑dependent (dichotomous) roles in cancer: TCGA analyses and functional perturbations show GPC4 expression associates with both poor and favorable prognosis depending on tumor type; mechanistic links to FGF/TGF and cell‑cycle pathways reported.|(hansson2024dichotomouseffectsof pages 15-17)|https://doi.org/10.3390/ijms25073945|2024-04|
|Biomarker / clinical associations|Circulating GPC4 associated with metabolic traits (insulin resistance, obesity/PCOS signals) and linked to cognitive/vascular risk in Parkinson’s disease cohorts — proposed as a candidate serum biomarker in multiple contexts.|(hansson2024dichotomouseffectsof pages 15-17, yu2025heparansulfateproteoglycans pages 29-30)|https://doi.org/10.3390/ijms25073945, https://doi.org/10.20944/preprints202506.2045.v1|2024-04, 2025-06|
|Recent experimental evidence & methods (2023–2024)|Activity‑dependent proximity labeling and synaptic trafficking studies (2024) support dynamic surface exposure/trafficking of synaptic proteins and note astrocyte‑secreted GPC4 as a modulator of synaptic protein release and AMPA recruitment.|(yu2025heparansulfateproteoglycans pages 29-30, hansson2024dichotomouseffectsof pages 15-17)|https://doi.org/10.20944/preprints202506.2045.v1, https://doi.org/10.3390/ijms25073945|2025-06, 2024-04|


*Table: Concise, well‑cited summary of human GPC4 (UniProt O75487) covering identity, structure, PTMs, localization, functions, interactions, disease links, and recent experimental evidence; useful as a one‑page reference with source links for follow‑up reading.*

Source details (URLs and dates are embedded in references above).


References

1. (hansson2024dichotomouseffectsof pages 15-17): Victor Chérouvrier Hansson, Fang Cheng, Grigorios Georgolopoulos, and Katrin Mani. Dichotomous effects of glypican-4 on cancer progression and its crosstalk with oncogenes. International Journal of Molecular Sciences, 25:3945, Apr 2024. URL: https://doi.org/10.3390/ijms25073945, doi:10.3390/ijms25073945. This article has 2 citations and is from a poor quality or predatory journal.

2. (piao2025unravelingglypican3from pages 1-2): Qianling Piao, Xiaona Bian, Qi Zhao, and Luguo Sun. Unraveling glypican-3: from structural to pathophysiological roles and mechanisms—an integrative perspective. Cells, 14:726, May 2025. URL: https://doi.org/10.3390/cells14100726, doi:10.3390/cells14100726. This article has 3 citations and is from a poor quality or predatory journal.

3. (piao2025unravelingglypican3from pages 17-18): Qianling Piao, Xiaona Bian, Qi Zhao, and Luguo Sun. Unraveling glypican-3: from structural to pathophysiological roles and mechanisms—an integrative perspective. Cells, 14:726, May 2025. URL: https://doi.org/10.3390/cells14100726, doi:10.3390/cells14100726. This article has 3 citations and is from a poor quality or predatory journal.

4. (yu2025heparansulfateproteoglycans pages 29-30): Chieh Yu, Duy LB Nguyen, Martina Gyimesi, Ian W Peall, Son H Pham, Lyn R Griffiths, Rachel K Okolicsanyi, and Larisa M. Haupt. Heparan sulfate proteoglycans mediate in vitro human neuronal lineage specification. Jun 2025. URL: https://doi.org/10.20944/preprints202506.2045.v1, doi:10.20944/preprints202506.2045.v1.

5. (hansson2024dichotomouseffectsof pages 1-2): Victor Chérouvrier Hansson, Fang Cheng, Grigorios Georgolopoulos, and Katrin Mani. Dichotomous effects of glypican-4 on cancer progression and its crosstalk with oncogenes. International Journal of Molecular Sciences, 25:3945, Apr 2024. URL: https://doi.org/10.3390/ijms25073945, doi:10.3390/ijms25073945. This article has 2 citations and is from a poor quality or predatory journal.

## Citations

1. yu2025heparansulfateproteoglycans pages 29-30
2. hansson2024dichotomouseffectsof pages 15-17
3. hansson2024dichotomouseffectsof pages 1-2
4. https://doi.org/10.3390/ijms25073945
5. https://doi.org/10.20944/preprints202506.2045.v1
6. https://doi.org/10.3390/cells14100726
7. https://doi.org/10.20944/preprints202506.2045.v1,
8. https://doi.org/10.3390/ijms25073945|2025-06,
9. https://doi.org/10.20944/preprints202506.2045.v1|2025-06|
10. https://doi.org/10.3390/ijms25073945,
11. https://doi.org/10.20944/preprints202506.2045.v1|2024-04,
12. https://doi.org/10.3390/ijms25073945|2024-04|
13. https://doi.org/10.3390/cells14100726,